**18. References**


VIIa, and this complex (TF:VIIa) may then activate factor X and factor IX217. Factor Xa, associated with factor Va, forms the prothrombinase complex, which subsequently turns

The relationship between coagulation and inflammation is complex and, as yet, not completely understood. It is known that blood clotting not only leads to fibrin deposition and platelet activation, but it also results in vascular cell activation, which contributes to leukocyte activation218. On the other hand, inflammation can induce TF expression in monocytes, via nuclear factor kappa-B (NF-kB) activation, thus initiating coagulation216.

Examples of this interaction are readily seen. First, leukocytes are found at relatively high concentrations in venous thrombi, and leukocytes and activated platelets can form rosettes

These microscopic observations are probably elicited from the actions of thrombin, which can activate platelets and endothelium, increasing the surface expression of P-selectin221,222. P- electin is the primary initial mediator of leukocyte-endothelial cell rolling and is critical for leukocyte adhesion. Second, TF:VIIa and factor Xa have been shown to activate cells and generate responses similar to those mediated by thrombin218. Third, GAG and TM expression on cell surfaces are inhibited by inflammatory cytokines 223,224,225,226 and lipopolysaccharide (LPS)227, thus blocking the augmentation of AT action by GAG, and APC

[1] Fowkes FJI, Price JF, Fowkes FGR. Incidence of diagnosed deep vein thrombosis in the general population: systematic review. *Eur J Vasc Endovasc Surg* 2003; 25: 1–5. [2] Heit JA, Silverstein MD, Mohr DN, et al. The epidemiology of venous thromboembolism

[3] Stein PD, Patel KC, Kalra NK, et al. Deep venous thrombosis in a general hospital. *Chest* 

[4] Kniffin WD, Baron JA, Barrett J, Birkmeyer JD, Anderson FA Jr. The epidemiology of

[5] Heit JA, O'Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein

[6] Cushman M, Tsai AW, White RH, et al. Deep vein thrombosis and pulmonary embolism

[7] Patel RK, Lambie J, Bonner L, Arya R. Venous thromboembolism in the black

[8] Klatsky AL, Armstrong MA, Poggi J. Risk of pulmonary embolism and/or deep venous

[9] Anderson FA, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the

embolism: the Worcester DVT Study. *Arch Intern Med* 1991; 151: 933–38.

thrombosis in Asian-Americans. *Am J Cardiol* 2000; 85: 1334–37.

diagnosed pulmonary embolism and deep venous thrombosis in the elderly. *Arch* 

thrombosis and pulmonary embolism: a population-based study. *Arch Intern Med* 

in two cohorts: the longitudinal investigation of thromboembolism etiology. *Am J* 

hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary

in the community. *Thromb Haemost* 2001; 86: 452–63.

population. *Arch Intern Med* 2004; 164: 1348–49.

mediated by P-selectin expression on the surface of the activated platelet 219,220.

prothrombin into thrombin.

formation by TM.

**18. References** 

2002; 122: 960–62.

2002; 162: 1245–48.

*Med* 2004; 117: 19–25.

*Intern Med* 1994; 154: 861–66.


Risk Factors of Deep Vein Thrombosis 21

[46] Farmer RD, Lawrenson RA, Todd JC, et al. A comparison of the risks of venous

[47] Pannaciulli N, De Mitrio V, Marino R, et al. Effect of glucose tolerance status on PAI-1 plasma levels in overweight and obese subjects. Obes Res 2002; 10:717e25. [48] De Pergola G, Pannacciulli N. Coagulation and fibrinolysis abnormalities in obesity. J

[49] Mertens I, Van Gaal LF. Obesity, haemostasis and the fibrinolytic system. Obes Rev

[50] Bara L, Nicaud V, Tiret L, et al. Expression of a paternal history of premature

[51] Rosengren A, Frede´n M, Hansson PO, et al. Psychosocial factors and venous

[52] Glynn RJ, Rosner B. Comparison of risk factors for the competing risks of coronary

[53] Homans J. Thrombosis of the deep leg veins due to prolonged sitting. N Engl J Med

[56] Cruickshank JM, Gorlin R, Jennett B. Air travel and thrombotic episodes: the economy

[57] Collins J. Thromboembolic disease related to air travel: what you need to know. Semin

[58] Hertzberg SR, Roy S, Hollis G, et al. Acute symptomatic pulmonary embolism associated with long haul air travel to Sydney. Vasc Med 2003;8:21e3. [59] Perez-Rodriguez E, Jimenez D, Diaz G, et al. Incidence of air travel-related pulmonary embolism at the Madrid-Barajas airport. Arch Intern Med 2003; 163:2766e70. [60] Hughes RJ, Hopkins RJ, Hill S, et al. Frequency of venous thromboembolism in low to

[61] Cogo A, Bernardi E, Prandoni P, et al. Acquired risk factors for deep-vein thrombosis in

[62] Lewis MA. The epidemiology of oral contraceptive use: a critical review of the studies

[63] Realini JP, Goldzieher JW. Oral contraceptives and cardiovascular disease: a critique of

[64] Vandenbroucke JP, Rosing J, BloemenkampK W, et al. Oral contraceptives and the risk

[65] Gerstman BB, Piper JM, Tomita DK, et al. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991;133:32e7.

the epidemiologic studies. Am J Obstet Gynecol 1985;152:729e98.

moderate risk long distance air travellers: the New Zealand Air Traveller's

on oral contraceptives and the health of young women. Am J Obstet Gynecol

[54] Tardy B, Page Y, Zeni F, et al. Phlebitis following travel. Presse Med 1993;22:811e4.

[55] Simpson K. Shelter deaths from pulmonary embolism. Lancet 1940;2:744.

Thrombosis (NZATT) study. Lancet 2003;362:2039e44.

of venous thrombosis. N Engl J Med 2001;344:1527e35.

symptomatic outpatients. Arch Intern Med 1994;154:164e8.

myocardial infarction on fibrinogen, factor VIIC and PAI-1 in European offspringethe EARS study. European Atherosclerosis Research Study Group.

thromboembolism: a long-term follow-up study of Swedish men. J Thromb

heart disease, stroke, and venous thromboembolism. Am J Epidemiol

Br J Clin Pharmacol 2000;49:580e90.

Endocrinol Invest 2002;25:899e904.

Thromb Haemost 1994;71:434e40.

class syndrome. Lancet 1988;2:497e8.

Haemost 2008;6:558e64.

Roentgenol 2005;40:1e2.

1998;179:1086e97.

2005;162:975e82.

1954;250:148e9.

2002;3:85e101.

thromboembolic disease in association with different combined oral contraceptives.


2010.

[28] Sugerman HJ, Sugerman EL, Wolfe L, et al. Risks and benefits of gastric bypass in

[29] Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest

[30] Caprini JA. Thrombosis risk assessment as a guide to quality patient care. Dis Mon

[31] Stein PD, Beemath A, Matta F, et al. Clinical characteristics of patient with acute pulmonary embolism: data from PIOPED II. Am J Med 2007;120:871e9. [32] Stein PD, Terrin ML, Hales CA, et al. Clinical, laboratory, roentgenographic and

[33] Heit JA, Silverstein MD, Mohr DN, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost 2001;86:452e63. [34] Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. The prevalence of risk factors for

[35] Hedley AA, Ogden CL, Johnson CL, et al. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999e2002. JAMA 2004;291:2847e50. [36] Goldhaber SZ, Grodstein F, Stampfer MJ, et al. A prospective study of risk factors for

[37] Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the

[38] Coon WW, Coller FA. Some epidemiologic considerations of thromboembolism. Surg

[39] Basili S, Pacini G, Guagnano MT, et al. Insulin resistance as a determinant of platelet

[40] Hansson PO, Eriksson H, Welin L, et al. Smoking and abdominal obesity: risk factors

[41] Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000;160: 3415e20. [42] Kabrhel C, Varraso R, Goldhaber SZ, et al. Prospective study of BMI and the risk of pulmonary embolism in women. Obesity (Silver Spring) 2009; 17:2040e6. [43] Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and

[44] US Department of Health and Human Services. Public Health Service, National Center

[45] Stein PD, Beemath A, Olson RE. Obesity as a risk factor in venous thromboembolism.

pre-existing cardiac or pulmonary disease. Chest 1991;100:598e603

pulmonary embolism in women. JAMA 1997;277:642e5.

activation in obese women. J Am Coll Cardiol 2006;48:2531e8.

6.

2001;119:132S–75S.

2005;51:70–8.

1992;152:1660e4.

Haemost 2003;89:493e8.

2000;160:809e15.

Am J Med 2005;118:978e80.

2010.

Gynecol Obstet 1959;109:487e501.

1913". Arch Intern Med 1999;159:1886e90.

Public-Use Data File Documentation. Available at:

morbidly obese patients with severe venous stasis disease. Ann Surg 2001;234:41–

electrocardiographic findings in patients with acute pulmonary embolism and no

venous thromboembolism among hospital patients. Arch Intern Med

interaction with coagulation factor levels and oral contraceptive use. Thromb

for venous thromboembolism among middle-aged men: "the study of men born in

pulmonary embolism: a population-based case-control study. Arch Intern Med

for Health Statistics National Hospital Discharge Survey 1979-2006 Multi-year

http://www.cdc.gov/nchs/about/major/hdasd/nhds.htm. Accessed April 28,


Risk Factors of Deep Vein Thrombosis 23

[85] Nicolaes GAF, Dahlback B. Activated protein C resistance (FVLeiden) and thrombosis:

[86] Koppelman SJ, Hackeng TM, Sixma JJ et al. Inhibition of the intrinsic factor X activating

[87] Allaart CF, Poort SR, Rosendaal FR et al. Increased risk of venous thrombosis in carriers of hereditary protein C defi ciency defect, Lancet. 1993. 341: 134–138. [88] Silver D, Vouyouka A. The caput medusae of hypercoagulability, J Vasc Surg. 2000. 31:

[91] Asherson RA, Khamashta MA, Ordi-Ros J, et al.The "primary" antiphospholipid

[92] Vianna JL, Khamashta MA, Ordi-Ros J, et al. Comparison of the primary and secondary

[93] Stein PD, Hull RD, Matta F, et al. Incidence of thrombocytopenia in hospitalized patients with venous thromboembolism. Am J Med 2009;122: 919e30. [94] Brick W, Burgess R, Faguet GB. Dysfibrinogenemia. WebMD. Available at:

[95] Shively BK. Deep venous thrombosis prophylaxis in patients with heart disease. Curr

[96] Jafri SM, Ozawa T, Mammen E, et al. Platelet function, thrombin and fibrinolytic

[97] Dries DL, Rosenberg YD, Waclawiw MA, et al. Ejection fraction and risk of

[98] Kyrle PA, Korninger C, Gossinger H, et al. Prevention of arterial and pulmonary

[99] Nordstro¨m M, Lindblad B, Bergqvist D, et al. A prospective study of the incidence of

[100] Segal JP, Harvey WP, Gurel T. Diagnosis and treatment of primary myocardial

[101] Roberts WC, Siegel RJ, McManus BM. Idiopathic dilated cardiomyopathy: analysis of

[102] Beemath A, Stein PD, Skaf E, et al. Risk of venous thromboembolism in patients

[103] Howell MD, Geraci JM, Knowlton AA. Congestive heart failure and outpatient risk of

venous thromboembolism: a retrospective, case-control study. J Clin Epidemiol

thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. J

embolism by oral anticoagulants in patients with dilated cardiomyopathy. Thromb

deep-vein thrombosis within a defined urban population. J Intern Med

activity in patients with heart failure. Eur Heart J 1993;14:205e12.

syndrome: major clinical and serological features. Medicine (Baltimore)

antiphospholipid syndrome: a European Multicenter Study of 114 patients. Am J

[89] Greaves M. Antiphospholipid antibodies and thrombosis. Lancet 1999;353:1348e53. [90] Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med

2003. 17: 37–61.

396–495.

2002;346: 752e63.

1989;68:366e74.

Med 1994;96:3e9.

Cardiol Rep 2001;3:56e62.

Haemost 1985;54:521e3.

1992;232:155e60.

2001;54:810e8166.

Am Coll Cardiol 1997;29:1074e80.

disease. Circulation 1965;32:837e44.

152 necropsy patients. Am J Cardiol 1987;60:1340e55.

hospitalized with heart failure. Am J Cardiol 2006;98:793e5.

www.webmd.com. Accessed March 19, 2010.

Blood. 1995. 86:1062–1071.

Factor V mutations causing hypercoagulable states, Hematol Oncol Clin N Am.

complex by protein S: Evidence for specifi c binding of protein S to factor VIII,


[66] Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism.

[67] World Health Organization Collaborative Study of Cardiovascular Disease and Steroid

[68] Helmrich SP, Rosenberg L, Kaufman DW, et al. Venous thromboembolism in relation to

[69] Pomp ER, le Cessie S, Rosendaal FR, et al. Risk of venous thrombosis: obesity and its

[70] Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism: a fiveyear national case-control study. Contraception 2002;65:187e96. [71] Nightingale AL, Lawrenson RA, Simpson EL, et al. The effects of age, body mass index,

[73] Duggan C, Marriott K, Edwards R, et al. Inherited and acquired risk factors for venous

[74] Meier CR, Jick H. Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin

[75] Daly E, Vessey MP, Hawkins MM, et al. Risk of venous thromboembolism in users of

[76] Varas-Lorenzo C, Garc´a-Rodriguez L, Cattaruzzi C, et al. Hormone replacement

[77] Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases

[78] Peverill RE. Hormone therapy and venous thromboembolism. Best Pract Res Clin

[79] Whiteman T, Hassouna HI. Hypercoagulable States, Hem/Onc Clin N Am. 2000. 14: 2. [80] Bick RL. Prothrombin G20210A mutation, antithrombin, heparin cofactor II, protein C,

[81] Johnson CM, Mureebe L, Silver D. Hypercoagulable states: A review, Vasc Endovasc

[84] Bick RL. Prothrombin G20210A mutation, antithrombin, heparin cofactor II, protein C,

[82] Bick RL. Clinical relevance of antithrombin III, Semin Thromb Hemost. 1982. 8: 276. [83] Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis, N Engl J Med.

based study in southern Europe. Am J Epidemiol 1998;147:387e90.

and protein S defects, Hematol Oncol Clin N Am. 2003. 17: 9–36.

and protein S defects, Hematol Oncol Clin N Am. 2003. 17: 9–36.

hormone replacement therapy. Lancet 1996;348:977e80.

Replacement Study. Ann Intern Med 2000;132:689e96.

Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet

joint effect with oral contraceptive use and prothrombotic mutations. Br J Haemotol

smoking and general health on the risk of venous thromboembolism in users of combined oral contraceptives. Eur J Contracept Reprod Healthcare 2000;5:265e74. [72] Decensi A, Maisonneuve P, Rotmensz N, et al. Italian Tamoxifen Study Group. Effect of

tamoxifen on venous thromboembolic events in a breast cancer prevention trial.

thromboembolic disease among women taking tamoxifen to prevent breast cancer.

therapy and the risk of hospitalization for venous thromboembolism: a population-

risk for venous thromboembolic disease. The Heart and Estrogen/progestin

A casecontrol study. Contraception 1998;57:291e301.

oral contraceptive use. Obstet Gynecol 1987;69:91e5.

1995;346:1575e82.

2007;139:289e96.

Circulation 2005;111:650e6.

J Clin Oncol 2003;21:3588e93.

Endocrinol Metab 2003;17:149e64.

Surg. 2005. 39: 123–133.

2001. 344: 1222–1231.

Pharmacol 1998;45:608e12.


Risk Factors of Deep Vein Thrombosis 25

[122] Skaf E, Stein PD, Beemath A, et al. Fatal pulmonary embolism and stroke. Am J

[123] Dismuke SE, VanderZwaag R. Accuracy and epidemiological implications of the death certificate diagnosis of pulmonary embolism. J Chronic Dis 1984;37:67e73. [124] Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton 3rd LJ. Risk

[125] Spencer FA, Lessard D, Emery C, Reed G, Goldberg RJ. Venous thromboembolism in

[126] Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, et al. Rates

[127] Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk

[128] Stein PD, Beemath A, Meyers FA, et al. Incidence of venous thromboembolism in

[129] Khorana AA, Francis CW, Culakova E, et al. Thromboembolism in hospitalized

[130] Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002;87:575–9. [131] Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic

analysis using Medicare claims data. Medicine (Baltimore) 1999;78:285–91. [132] Stein PD, Beemath A, Meyers FA, et al. Incidence of venous thromboembolism in

[133] Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its

[134] Numico G, Garrone O, Dongiovanni V, et al. Prospective evaluation of major vascular

[135] Weijl NI, Rutten MF, Zwinderman AH, et al. Thromboembolic events during

[136] White RH, Chew HK, Zhou H, et al. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med 2005;165:1782–7. [137] Blom JW, Doggen CJ, Osanto S, et al. Malignancies, prothrombotic mutations, and the

[138] Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002;87:575–9. [139] Khorana AA, Francis CW, Culakova E, et al. Thromboembolism in hospitalized

[140] Rodriguez AO, Wun T, Chew H, et al. Venous thromboembolism in ovarian cancer.

case-control study. Arch Intern Med 2000;160(6):809–15.

Medicine (Baltimore) 1999;78(5):285–91.

patients. Cancer 2007;110(10):2339–46.

gemcitabine. Cancer 2005;103:994–9.

risk of venous thrombosis. JAMA 2005;293:715–22.

neutropenic cancer patients. J Clin Oncol 2006;24:484–90.

Clin Oncol 2000;18:2169–78.

Gynecol Oncol 2007;105:784–90.

2006;166:458–64.

the outpatient setting. Arch Intern Med 2007;167(14):1471–5.

patients hospitalized with cancer. Am J Med 2006;119:60–8.

patients hospitalized with cancer. Am J Med 2006;119:60–8.

neutropenic cancer patients. J Clin Oncol 2006;24:484–90.

factors for deep vein thrombosis and pulmonary embolism: a populationbased

ofinitial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data.

factors, and trends for venous thromboembolism among hospitalized cancer

disease among patients with malignancy versus those without malignancy. Risk

effect on survival among patients with common cancers. Arch Intern Med

events in patients with nonsmall cell lung carcinoma treated with cisplatin and

chemotherapy for germ cell cancer: a cohort study and review of the literature. J

Cardiol 2006;97:1776e7.


[104] Beemath A, Skaf E, Stein PD. Pulmonary embolism as a cause of death in adults who

[105] Attems J, Arbes S, Bohm G, et al. The clinical diagnostic accuracy rate regarding the

[106] Hsu DT, Addonizio LJ, Hordof AJ, Gersony WM. Acute pulmonary embolism in

[107] Cohen AT, Tapson VF, Bergmann JF, et al. Venous thromboembolism risk and

[108] Mispelaere D, Glerant JC, Audebert M, et al. Pulmonary embolism and sibilant types

[109] Tillie-Leblond I, Marquette CH, Perez T, et al. Pulmonary embolism in patients with

[110] Stein PD, Beemath A, Meyers FA, et al. Pulmonary embolism and deep venous

[111] Neuhaus A, Bentz RR, Weg JG. Pulmonary embolism in respiratory failure. Chest

[112] Schonhofer B, Kohler D. Prevalence of deep-vein thrombosis of the leg in patients with

[113] Gunduz *S,* Ogur E, Mohur H, et al: Deep vein thrombosis in spinal cord injured

[114] Hull R Venous thromboembolism in spinal cord injury patients Chest 102:658-662,

[115] Merli GJ: Management of deep vein thrombosis in spinal cord injury. Chest 102652-

[116] Myllynen P, Kammonen M, Rokkanen P, et al: Deep venous thrombosis and

[117] Prasad DK, Banerjee AK, Howard H Incidence of deep vein thrombosis and the effect

[118] Waring WP, Karunas RS: Acute spinal cord injuries and the incidence of clinically

[119] Yao JST Deep vein thrombosis in spinal cord-injured patients. Evaluation and

[120] Harvey RL. Prevention of venous thromboembolism after stroke. Topics Stroke Rehab

[121] Skaf E, Stein PD, Beemath A, et al. Venous thromboembolism in patients with ischemic

occurring thromboembolic disease. Paraplegia 29:8-16, 1991

and hemorrhagic stroke. Am J Cardiol 2005;96:1731e3.

pulmonary embolism in patients with acute spinal cord injury: A comparison with non-paralyzed patients immobilized due to spinal fractures. J Trauma 25:541-543,

of the pneumatic compression if the calf in elderly hemiplegics. Age Aging 11:424,

immediate cause of death in a hospitalized geriatric population; an autopsy study

pediatric patients awaiting heart transplantation. J Am Coll Cardiol 1991;17:1621–5.

prophylaxis in the acute hospital care setting (ENDORSE study): a multinational

of chronic obstructive pulmonary disease decompensations. Rev Mal Respir

unexplained exacerbation of chronic obstructive pulmonary disease: prevalence

thrombosis in patients hospitalized with chronic obstructive pulmonary disease. J

acute exacerbation of Chronic Obstructive Pulmonary Disease. Respiration

died with heart failure. Am J Cardiol 2006;98:1073e5.

cross-sectional study. Lancet 2008;371: 387-94.

and risk factors. Ann Intern Med 2006;144:390e6.

2002;19:415e23.

1978;73(4):460 –5.

1998;65:173– 7.

1992

1985

1982

2003;10:61e9.

657, 1992

Cardiovasc Med 2007;8:253e7.

patients. Paraplegia 31:606410, 1993

assessment. Chest 102:645-648, 1992

of 1594 patients. Wien Med Wochenschr 2004;154:159e62.


Risk Factors of Deep Vein Thrombosis 27

[161] Anonymous. Oral contraception and thromboembolic disease. J R Coll Gen Pract

[162] Ginsberg JS, Brill-Edwards P, Burrows RF, Bona R, Prandoni P, Buller HR, et al.

[163] Ikard RW, Ueland K, Folse R. Lower limb venous dynamics in pregnant women. Surg

[164] Macklon NC, Greer IA, Bowman AW. An ultrasound study of gestational and postural

[165] Metcalfe J, Ueland K. Maternal cardiovascular adjustments to pregnancy. Prog

[166] Kerr MG, Scott DB, Samuel E. Studies of the inferior vena cava in late pregnancy. Br

[169] Rutherford SE, Phelan JP. Thromboembolic disease in pregnancy. Clin Perinatol

[170] Stirling Y, Woolf L, North WR, Seghatchian MJ, Meade TW. Haemostasis in normal

[171] Woodhams BJ, Candotti G, Shaw R, Kernoff PB. Changes in coagulation and

[172] Bonnar J. Blood coagulation and fibrinolysis in obstetrics. Clin Hematol 1973;12:58 –

[173] Comp PC, Thurnau GR, Welsh J, Esmon CT. Functional and immunologic protein S

[174] Clark P, Brennand J, Conkie JA, McCall F, Greer IA, Walker ID. Activated protein C

[175] Wright JG, Cooper P, Astedt B, Lecander I, Wilde JT, Preston FE, et al. Fibrinolysis

[176] Bremme K, Ostlund E, Almqvist I, Heinonen K, Blomback M. Enhanced thrombin

[177] Kruithof EK, Tran-Thang C, Gudinchet A, Hauert J, Nicoloso G, Genton C, et al.

[178] McColl MD, Ramsay JI, Tait RD, Walker ID, McCall F, Conkie JA, et al. Risk factors for

[167] Cockett FB, Thomas ML. The iliac compression syndrome. Br J Surg 1965;52:816– 21. [168] Hull RD, Raskob GE, Carter CJ. Serial impedance plethysmography in pregnant

Venous thrombosis during pregnancy: leg and trimester of presentation. Thromb

changes in the deep venous system of the leg in pregnancy. Br J Obstet Gynaecol

patients with clinically suspected deep vein thrombosis. Ann Intern Med

fibrinolysis during pregnancy: evidence of activation of coagulation preceding

sensitivity, protein C, protein S, and coagulation in normal pregnancy. Thromb

during normal human pregnancy: complex interrelationships between plasma levels of tissue plasminogen activator and inhibitors and the euglobulin clot lysis

generation and fibrinolytic activity in normal pregnancy and the puerperium.

Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. Blood

pregnancy associated venous thromboembolism. Thromb Haemost 1997;78:1183–8.

1967;13: 267e79.

1997;104:191–7.

Med J 1964;1:532– 3.

1990;112:663– 7.

1986;13:719– 39.

Haemost 1998;79:1166– 70.

time. Br J Haematol 1988; 69:253– 8.

Obstet Gynecol 1992;80:132– 7.

1987;69:460–6.

63.

Haemost 1992;67:519– 20

Gynecol Obstet 1971;132:483– 8.

Cardiovasc Dis 1974;16:363–74.

pregnancy. Thromb Haemost 1984;52:176–82.

spontaneous abortion. Thromb Res 1989;55:99– 107.

levels are decreased during pregnancy. Blood 1986;68:881– 5.


[141] Tateo S, Mereu L, Salamano S, et al. Ovarian cancer and venous thromboembolic risk.

[142] Chew HK, Wun T, Harvey DJ, et al. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol 2007;25:70–6. [143] Chew HK, Davies AM,Wun T, et al. The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost 2008;6:601–8. [144] Alcalay A, Wun T, Khatri V, et al. Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol 2006;24:1112–8. [145] Mandala M, Reni M, Cascinu S, et al. Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. Ann Oncol 2007;18:1660–5. [146] Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its

effect on survival among patients with common cancers. Arch Intern Med

pulmonary embolism: a populationbased case-control study. Arch Intern Med

with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical

negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997;89:1673–

adjuvant hormone therapy for breast carcinoma: a systematic review. Cancer

undergoing major abdominal surgery: emerging options. J Surg Oncol 2007;96:265–

venous thromboembolism in a prospective observational study. Cancer

[147] Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and

[148] Pritchard KI, Paterson AH, Paul NA, et al. Increased thromboembolic complications

[150] Deitcher SR, Gomes MP. The risk of venous thromboembolic disease associated with

[151] Agnelli G, Caprini JA. The prophylaxis of venous thrombosis in patients with cancer

[152] Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 2003;21:3665–75. [153] Khorana AA, Francis CW, Culakova E, et al. Risk factors for chemotherapy-associated

[154] Edgington TS, Mackman N, Brand K, et al. The structural biology of expression and

[157] Khorana AA, Ahrendt SA, Ryan CK, et al. Tissue factor expression, angiogenesis, and

[158] Stein PD, Beemath A, Meyers FA, et al. Incidence of venous thromboembolism in

[159] Stein PD, Beemath A, Meyers FA, et al. Pulmonary embolism as a cause of death in

[160] Stein PD, Hull RD, Kayali F, et al. Venous thromboembolism in pregnancy: 21 year

function of tissue factor. Thromb Haemost 1991;66:67–79. [155] Nemerson Y. Tissue factor and hemostasis. Blood 1988;71:1–8.

[156] Nemerson Y. Tissue factor: then and now. Thromb Haemost 1995;74:180–4.

thrombosis in pancreatic cancer. Clin Cancer Res 2007;13:2870–5.

patients hospitalized with cancer. Am J Med 2006;119:60e8.

patients who died with cancer. Am J Med 2006;119:163e5.

trends. Am J Med 2004;117:121e5.

Trials Group Breast Cancer Site Group. J Clin Oncol 1996;14:2731–7. [149] Fisher B, Dignam J, Wolmark N, et al. Tamoxifen and chemotherapy for lymph node-

Gynecol Oncol 2005;99:119–25.

2006;166:458–64.

2000;160:809–15.

2004;101:439–49.

2005;104:2822–9.

82.

72.


Risk Factors of Deep Vein Thrombosis 29

[198] Saleh T, Matta F, Alali F, et al. Liver disease and risk of venous thromboembolism.

[199] Søgaard KK, Horva´th-Puho´ E, Grønbaek H, et al. Risk of venous thromboembolism

[200] Northup PG, McMahon MM, Ruhl AP, et al. Coagulopathy does not fully protect

[201] Tripodi A, Primignani M, Chantarangkul V, et al. An imbalance of pro- vs anti-

[202] Danescu L, Badshah A, Danescu SC, et al. Venous thromboembolism in patients hospitalized with thyroid dysfunction. Clin Appl Thromb Hemost 2009;15:676e80. [203] Seriolo B, Accardo S, Garnero A, et al. Anticardiolipin antibodies, free protein S levels

[204] McEntegart A, Capell HA, Creran D, et al. Cardiovascular risk factors, including

[205] Matta F, Singala R, Yaekoub AY, et al. Risk of venous thromboembolism with

[206] Stein PD, Goldman J, Matta F, et al. Diabetes mellitus and risk of venous

[207] Matta F, Yaekoub AY, Stein PD. Human immunodeficiency virus infection and risk of

[208] Kayali F, Najjar R, Aswad F, et al. Venous thromboembolism in patients hospitalized

[209] Stein PD, Beemath A, Meyers FA, et al. Deep venous thrombosis and pulmonary

[210] Navarro S, Ricart JM, Medina P, et al. Activated protein C levels in Behc¸ et's disease

[211] Ray JG, Burows RF, Ginsberg JS, et al. Paroxysmal nocturnal hemoglobinuria and the

[212] Fischer MD, Hopewell PC. Recurrent pulmonary emboli and Buerger's disease. West J

[213] Osterud B (1998) Tissue factor expression by monocytes: regulation and pathophysiological roles. Blood Coagul Fibrinolysis 9[Suppl 1]:S9–14 [214] Osterud B, Rapaport SI (1977) Activation of factor IX by the reaction product of tissue

[215] Esmon CT (2001) Role of coagulation inhibitors in inflammation. Thromb Haemost

embolism in patients hospitalized with sickle cell disease. Am J Med

risk of venous thrombosis: review and recommendations for management of the

factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl

rheumatoid arthritis. Thromb Haemost 2009;101:134e8.

venous thromboembolism. Am J Med Sci 2008;336:402e6.

and risk of venous thrombosis. Br J Haematol 2004;126:550e6.

pregnant and nonpregnant patient. Haemostasis 2000;30:103e17.

with nephrotic syndrome. Am J Med 2008;121:226e30.

thromboembolism. Am J Med Sic 2009;337:259e64.

in patients with liver disease: a nationwide population-based case-control study.

hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J

coagulation factors in plasma from patients with cirrhosis. Gastroenterology

and thrombosis: a survey in a selected population of rheumatoid arthritis patients.

thrombotic variables, in a population with rheumatoid arthritis. Rheumatology

Submitted for publication.

Am J Gastroenterol 2009;104: 96e101.

Gastroenterol 2006;101:1524e8.

Rheumatology 1999; 38:675e8.

2009;137:2105e11.

2001;40:640e4.

2006;119:897e901.

Med 1981; 135:238e41.

Acad Sci USA 74:5260–5264

86:51–56


[179] Geerts WH, Bergqvist D, Pineo GF, et al. Preventive of venous thromboembolism.

[180] Kroger K, Schelo C, Gocke C, et al. Colour Doppler sonographic diagnosis of upper

[181] Dollery CM, Sullivan ID, Bauraind O, et al. Thrombosis and embolism in long-term central venous access for parenteral nutrition. Lancet 1994;344: 1043e5. [182] Mustafa S, Stein PD, Patel KC, et al. Upper extremity deep venous thrombosis. Chest

[183] Hingorani A, Ascher E, Lorenson E, et al. Upper extremity deep venous thrombosis

[184] Monreal M, Lafoz E, Ruiz J, et al. Upperextremity deep venous thrombosis and

[185] Horattas MC, Wright DJ, Fenton AH, et al. Changing concepts of deep venous

[186] Joffe HV, Kucher N, Tapson VF, et al. Upper-extremity deep vein thrombosis: a

[187] Broviac JW, Cole JJ, Scribner BH. A silicone rubber atrial catheter for prolonged

[188] Hickman RO, Buckner CD, Clift RA, Sanders JE, Stewart P, Thomas ED. A modified

[189] Foley MJ. Radiologic placement of long-term central venous peripheral access system ports (PAS Port): results in 150 patients. J Vasc Interv Radiol1995; 6:255–262. [190] Rubenstein EB, Fender A, Rolston KV, et al. Vascular access by physician as-sistants:

[191] Shetty PC, Mody MK, Kastan DJ, et al. Outcome of 350 implanted chest ports placed

[192] Schwarz RE, Groeger JS, Coit DG. Subcutaneously implanted central venous access devices in cancer patients: a prospective analysis. Cancer 1997; 79: 1635–1640. [193] Struk DW, Bennett JD, Kozak RI. Insertion of subcutaneous central venous infusion ports by interventional radiologists. Can Assoc Radiol J 1995; 46:32–36. [194] Hata Y, Morita S, Morita Y, et al. Peripheral insertion of a central venous access device

[195] Deppe G, Kahn ML, Malviya VK, Malone JM, Christensen CW. Experience with the

[196] Monreal M, Lafoz E, Ruiz J, Valls R, Alastrue A. Upper extremity deep venous thrombosis and pulmonary embolism; a prospective study. Chest 1991;99:280–3. [197] Saleh T, Matta F, Yaekoub AY, et al. Risk of venous thromboembolism with

by interventional radiologists. J Vasc Interv Radiol 1997; 8:991–995.

forearm. Cardiovasc Intervent Radiol 1998; 21:230 –233.

Gynecol Oncol 1996; 62:340 –343.

print].

pulmonary embolism. A prospective study. Chest 1991;99:280e3.

prospective registry of 592 patients. Circulation 2004;110:1605e11.

parenteral alimentation. Surg Gynecol Obstet 1973; 136:602– 606.

recipients. Surg Gynecol Obstet 1979; 148:871– 875.

and its impact on morbidity and mortality rates in a hospitalbased population. J

thrombosis of the upper extremityereport of a series and review of the literature.

right atrial catheter for access to the venous system in marrow trans-plant

evaluation of an implantable peripheral port system in cancer patients. J Clin Oncol

under fluoroscopic guidance using a peripherally accessed system (PAS) port in the

P.A.S.-Port venous access device in patients with gynecologic malignancies.

inflammatory bowel disease. Clin Appl Thromb Hemost 2010. [Epub ahead of

(8th edition). Chest 2008;133: 381Se453S.

2003; 163:1213e9.

Vasc Surg 1997;26:853e60.

Surgery 1988;104:561e7.

1995; 13:1513–1519.

limb venous thromboses. Clin Sci 1998;94:657e61.

American College of Chest physicians evidence-based clinical practice guidelines


**2** 

*Kaunas, Lithuania* 

**Venous Stasis and Deep Vein Thrombosis** 

Mindaugas Kiudelis, Dalia Adukauskienė and Rolandas Gerbutavičius

Laparoscopic surgery – is one of the most progressive minimal invasive surgery branches. About 25–40% of all abdominal operations are performed laparoscopicaly in our days and this rating is going in ascending order. Laparoscopic operations (cholecystectomy, fundoplication, appendectomy, bypass due to morbid obesity et at.) have rapidly become the operations of choice in abdominal surgery. Several authors reported that deep vein thrombosis (DVT) in the legs developed in 30% of postoperative patients and pulmonary

Many studies explored the frequency of deep leg vein thrombosis after various open abdominal surgery operations. Some studies (Geerts and al.,1994) determined that deep leg vein thrombosis develops in 55% of polytrauma patients. Clagett &Reisch, 1988; found 25% rate of DVT after open abdominal surgery. Literature data on the incidence of DVT after laparoscopic operations is limited. Patel MI and al., 1996; carried out the prospective clinical study, studying the frequency of DVT after laparoscopic cholecystectomy. The rate of DVT, diagnosed by ultrasound Doppler, was 55%. The incidence of DVT and PE after laparoscopic fundoplications was 1.8% in our prospective randomized study. Lord RV and al., 1998; performed the prospective clinical study and compared the incidence of DVT after laparoscopic or microlaparotomic (open) cholecystectomy. The incidence of DVT was 1.7% after laparoscopic and 2.4% after open cholecystectomy. Nevertheless, many authors states, that the incidence of DVT should be less after laparoscopic surgery when comparing with open one. Laparoscopic operations, in comparison with open ones, have few basic differences: 1. Laparoscopic operation involves a specific manipulation called abdominal insufflation in addition to the routine procedure of general anesthesia. The increased intraabdominal pressure associated with pneumoperitoneum (12-14 mm Hg) during laparoscopic upper gastrointestinal surgery has the potential to compound any lower– limb venous stasis already present due to general anesthesia by compressing the

2. Most of laparoscopic operations often last more than 1.5 hours and often are performed with patient in the reverse Trendelenburg position. These differences also have the

**1. Introduction** 

embolism (PE) in 10% of these patients.

retroperitoneal vena cava and iliac veins.

potential for an increased risk of significant venous stasis.

**Prevention in Laparoscopic Surgery** 

*Medical Academy of Lithuanian University of Health Sciences,* 

